2Q PREVIEW: J&J's Janssen continues to drive earnings growth
This article was originally published in Scrip
Executive Summary
Johnson & Johnson’s fast-rising drug business has helped offset the slowing growth of the company’s medical devices business. When J&J announces second-quarter earnings July 16, drugs are expected to be the growth drivers again.